Could a vitamin B12 derivative help treat shock?
NCT ID NCT04964492
First seen Jun 27, 2026 ยท Last updated Jun 27, 2026
Summary
This study looked back at medical records of 18 intensive care patients who received hydroxocobalamin (a form of vitamin B12) for severe vasodilatory shock, a condition where blood vessels widen too much and blood pressure drops dangerously. The goal was to see if the treatment could raise blood pressure enough to reduce the need for other medications. The study was completed and focused on measuring blood pressure changes after the drug was given.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMODYNAMICS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU Amiens-Picardie
Amiens, 80054, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new Opioid-Like drug prevent dangerous blood pressure spikes during anesthesia?
- Can we predict superbug evolution in the ICU?
- A new device aims to track the heart's pumping power in the ICU โ without invasive tubes
- Could albumin boost oxygen delivery in sepsis? new trial investigates
- Life after a seizure emergency: study tracks hidden toll on mind and body
- Could a lower dose of spinal anesthetic protect elderly patients during surgery?